Claudia Parisi, Praticienne Specialiste at Centre Antoine Lacassagne and Editorial Board Member at BMJ Oncology, shared a post on LinkedIn:
“Just published.
Pleased and proud to share our work on NSCLC in Vulnerable and Special Populations on Journal of Thoracic Oncology JTO, IASLC International Association for the Study of Lung Cancer.
Addressing vulnerable populations and taking them into account represents a major challenge for oncologists. It is essential to take into account the reality of clinical practice, which differs from that of clinical trials, as we must confront comorbidities directly and acknowledge that clear guidelines are not always available.
We often have to build them through our own efforts and collaborations.”
Title: Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
Authors: Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano, Daniel W. Bowles, Robert C. Doebele, Aaron S. Mansfield, Christina S. Baik, Gilberto de Lima Lopes, Luis Paz-Ares, Matthew H. Taylor, Daniel S.W. Tan, Guzman Alonso, Shirish M. Gadgeel, Gregory P. Kalemkerian, Sai-Hong Ignatius Ou, Anthonie J. van der Wekken, Carlos R. Becerra, Makenzi Evangelist, Frank Griesinger, Stephen V. Liu, Yanyan Lou, Julien Mazières, Jason M. Melear, Mohit Narang, Ashish Saxena, Michael Thomas, Sophia Wang, Amber Thomassen, Dae Ho Lee, Dong-Wan Kim, Justin F. Gainor
Read The Full Article
Other articles about NSCLC on OncoDaily.